Meanwhile, other pharma companies are also developing checkpoint inhibitors for adjuvant RCC, including Roche ... which is testing its Imfinzi (durvalumab) alone and in combination with CTLA4 ...

Durvalumab is recommended, within its marketing authorisation, as neoadjuvant treatment with platinum-based chemotherapy, then continued alone as adjuvant treatment, for treating non-small-cell lung ...

Durvalumab (Imfinzi, AstraZeneca) with platinum-based chemotherapy as neoadjuvant treatment, and then as monotherapy after surgery, is indicated for 'the treatment of adults with resectable (tumours ≥ ...

Merck (MSD) has released data from the Phase III KEYNOTE-564 clinical trial of KEYTRUDA, an anti-programmed death receptor-1 (PD-1) therapy, for the adjuvant treatment of renal cell carcinoma (RCC ...

Medscape Medical News, February 08, 2024 GICS 2024 Durvalumab Plus Bevacizumab ... 2024 GUCS 2024 'Breakthrough': Adjuvant Pembro Ups Survival in Renal Cancer KEYNOTE-564 is the first trial ...